REFERENCIAS BIBLIOGRÁFICAS

1.    Lensing AWA, Pradoni P, Prins MH, Buller HR. Deep-vein thrombosis. (Seminar). Lancet 1999; 353: 479-85.
2.    Salzman EW, Hirsh J. The epidemiology, pathogenesis, and natural history of venous thrombosis. In: Colman R W, Hirsh J, 23 Marder VJ, Salzman EW, eds. Hemostasis and thrombosis: basic principles and clinical practice, Philadelphia: JB Lippincott 1275-98.
3.     Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep vein thrombosis. Ann Intern Med 1996;125:1-7.
4.     Anderson FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT study. Arch Intern Med 1991; 151: 933-38.
5.     Laffan M, Tuddenham E. Science, medicine, and the future: assessing thrombotic risk (Clinical Review). 1998; 317: 520-23.
6.     Silverstein HJA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1988; 158: 585.
7.     Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-60.
8.     Hansson PO, Werlin L, Tibblin G, Erikson H. Deep vein thrombosis and pulmonary embolism in the general populations. Arch Intern Med 1997; 157: 1665-70.
9.     Colman RW, Hirsh J, Murder VJ, Salzman EW. Hemostasis and thrombosis. Basic principles and clinical practice. Third Edition. J.B. Lippincott company. 1994.
10.     Sevitt S, Gallagher NG. Venous thrombosis and pulmonary embolism: a clinicopathological Study in injured and burner patients. Br J Surg 1961; 48: 475.
11.     White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 1998: 128: 737.
12.     Triplett DA. Antiphospholipid-protein antibodies: laboratory detection and clinical relevance. Throm Res 1995; 78: 1-31.
13.     WHO Collaborative study of cardiovascular disease and steroid hormone contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-82.
14.     Dahlback B, Carlson M, Svensson PJ. Familial thrombophilia due to previously unrecognized mechanism characterized by poor anticoagulant response to activate protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8
15.     Poort SR, Rosendaal FR, Reitma PH, Bertina RM. A common genetic variation in the 3-untranslated region od the protrombin gen is associated with elevated plasma prothrombin levels and increase in venous thrombosis. Blood 1996; 88: 3689-703.
16.. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-5.
17.     den Heijer M, Koster T, Blom HJ, et al. Hyperhomocystinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-62.
18.     Meijers JCM, Tekelenburg LH, Bouma VN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342: 696-701.
19.     Cooper DN, Krawczack M. Venous thrombosis from genes to clinical medicine. Oxford: Bios Scientific, 1997.
20.     Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 1999; 340: 1555-64.
21.     Douglas AS. Historical aspects of anticoagulant therapy. Anticoagulant Therapy, First ed. Oxford, Blackwell Scientific Publications; 1962.
22.    Fiore L, Deykin D. Anticoagulant therapy. Beutler E, Lichtman M, Coller B, Kipps T. Ed. Williams Hemathology 1995.
23.     Whitlon DS, Sadowski JA, Sutlie JW. Mechanisms of coumarin action: significate of vit K epoxide reductase inhibition. Biochemistry 1978; 17: 1371-77.
24.    Weitz JL. Low-molecular-weight heparin. N Engl J Med 1997; 337: 688-98.
25.     Anderson LO, Barrowcliffe TW, Holmer E, Johnson EA, Sims GEG. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antitrombin III and gelfiltrations. Thromb Res 1976; 9: 575.
26.     Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by plated factor 4. Biochem J 1984; 218: 725.
27.     Bara L, Billaud E, Gramond G, Kher A, Samama M. Comparative pharmacokinetics of a low molecular weight heparin and unfractioned heparin after intravenous and subcutaneous administration. Throm Res 1985; 39: 631-6
28.     Douketis JD, Kearon C, Bates S, Duku EK, Giusberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism (review). JAMA 1998; 279: 458-62.
29.     Chasan-Taber L, Stampfer MJ. Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med 1998; 128: 467.
30.     Devor M, Barrett-Conner E, Renvall M, Feikal D Jr, Ramsdell J. Estrogen replacement therapy and the risk of venous thromboembolism. Am J Med 1992; 92: 275.
31.     Venous thrombosis as a chronic disease. Editorial. N Engl J Med 1999; 340: 955-56.
32.     Weinmann EE, Salzman EW. Medical Progress: Deep-vein thrombosis. N Engl J Med 1994; 331:1630-41.
33.     Clive K. Diagnosis and management of venous thrombosis. The American Society of Hematology Education Program Book 1999. pag: 209-17.
34.     Lensing AWA, Hirsh J, Buller HR. Diagnosis of venous thrombosis. In Colman RW, Hirsh J, Marder VJ, Salzman EW, eds Hemostasis and thrombosis; Basic principles and clinical practice. Philadelphia: JB Lippincott, 1993: 1297-321.
35.     Lensing AWA, Prandoni P, Branjes D, et al. Detection of deep-vein, thrombosis by real time B modo ultrasonography N Engl J Med 1989; 320: 342-5.
36.     Davidson BL, Deppert EJ. Ultrasound for the diagnosis of deep-vein thrombosis: Where to now ? BMJ 1998; 316: 2-3.
37.     Wells PS, Anderson DR, Bormanis J, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 1997;350:1795-    98.
38.     Kraaijenhagen RA, Lensing AWA, Lijmer JC, et al. Diagnostic strategies for the management of a patients with clinically suspected deep-vein thrombosis. Curr Opin Pul Med 1997; 3: 268-74.
39.     Goldhaber SZ Pulmonary embolism. Medical progress. N Engl J Med 1998; 339: 93-104.
40.     Moser KM, Fedullo PF, Litte-John JK, Crawford R. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis. JAMA 1994; 271: 1908.
41.     Turstra F, Kuijer PMM, van Beek EJR, Brandjes DPM, ten Cate JW, Buller HR, Diagnostic utility of ultrasonography of leg veins in patients suspected of having pulmonary embolism. Ann Inter Med 1997; 12: 775-81.
42.     Goldhaber SZ, De Rosa M, Visani L. International cooperative pulmonary embolism registry detects high mortality rate. Circulation 1997; 96: suppl I: I-159.
43.    Bergvist D, Lindblad B. A 30 year survey of pulmonary embolism verified at autopsy: an analysis of 1,274 surgical patient. Br J Surg 1985;72:105-8.
44.     Bounamenaux H, de Moerloose P, Perrier A, Reber G. Plasma measurement of D-dimer as diagnostic aid in suspected venous thrombolism: An overview. Throm Haemost 1994;71:1-6.
45.     Ginsber JS, Wells PS, Kearon C, Anderson D, Crowther M, Weitz JI, Bormanis J, Brill-Edwards P, Turpie AGG, MacKinnon B, Gent M, Hirsh J. Sensitivity and specific of a rapid whole-blood assay for D-dimer in the diagnosis of pulmonary embolism. Ann Intern Med 1998; 129: 1006.
46.     de Moerloose P, Minazio P, Reber G, Perrier A, Bounameaux H. D-dimer determination to exclude pulmonary embolism: A two-step aproach using latex assay as screening toll. Throm Haemost 1994; 72: 89-91.
47.     Hull RD, Hirsh J, Carter CJ, et al. Pulmonary angiography, ventilation scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med 1983; 320: 342-5.
48.     Stein PD, Terrin ML, Gottschalk A, Alavi A, Henry JW. Value of ventilation/perfusion scans versus perfusion scan alone in acute pulmonary embolism. Am J Cardiol 1992; 69: 1239-41.
49. Remy JM, Deschildre F, et al. Diagnosis of pulmonary embolism with spiral CT: comparison with pulmonary angiography and scintigraphy. Radiology 1996; 200: 639-706.
50.     Meaney JFM, Wey JC, Chenevert TL, et al. Diagnosis of pulmonary embolism with magnetic resonance angiography. N Engl J Med 1997; 339: 93-104.
51.     Jardin F, Dubbourg O, Bourdarias JP. Echocardiographic pattern of acute cor pulmonale. Chest 1997; 111: 209-17.
52.     Ribeiro A, Lindmarker P, Juhlin-Dannfelt A, Johnsson H, Jorfeldt L. Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as predictor of mortality rate. Am Heart J 1997; 134: 479-87.
53.     Kasper W, Konstantinides S, Geiber A, et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of multicenter registry. J Am Coll Cardiolo 1997; 30: 1165-71.
54.     McConnell MV, Solomon SD, Rayan ME, Come PC, Goldhaber SR, Lee RT. Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism. Am J Cardiol 1996; 78: 469-73.
55.     Decousus H, Leizorovics A, Parent F, et al. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 1998; 338: 409-15.
56.     Karp RB, Wylie EJ. Recurrent thrombosis after iliofemoral venous thrombectomy- Sur Forum 1966; 17: 147-53.
57.     Kening R, Cribier A, Gerber L, et al. A new treatment for severe pulmonary embolism percutaneous rheolytic thrombectomy. Circulation 1997; 96: 2498-500.
58.     Konstantinides S, Geibel A, Olschewski M, et al. Association between thrombolytic treatment and prognosis of hemodynamically stable patients with major pulmonary embolism: results of multicenter registry. Circulation 1997; 96: 882-8.
59.     Jerjes-Sanchez C, Ramirez-Rivera A, García ML, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: A randomized controlled trial. J Thromb Thrombolysis 1995; 2: 227-9.
60.     Nikkola KM, Patel SR, Parker JA, Rodstein F, Goldhaber SZ. Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis. Am Heart J 1997; 134: 69-72.
61.     Weitz J. Treatment of venous thromboembolism. The American Society of Hematology Education Program Book.1999 pp: 218-22.
62.     Brandjes DPM, Heijbôer H, Buller HR, de Rijk M, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis. N Engl J Med 1992; 327: 1485-9.
63.     Knamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRP. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 1995; 332: 993-7.
64.     Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315: 1109.
65.     Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thrombo Haemost 1992; 67: 639.
66.     Young E, Cosmi B, Weitz J, Hirsh J. Comparison of the non specific binding of unfractionated heparin and low molecular weight heparin to plasma proteins. Throm Haemost 1993; 70: 625.
67.     Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-98.
68.     Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130: 800.
69.     The Columbus Investigators. Low molecular weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 657.
70.     Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990: 322: 1250.
71.     Pini M, Aiell S, Manotti C, et al. Low-molecular-weight heparin in the prevention of recurrences after deep vein thrombosis. Throm Haemost 1994; 72: 191.
72.     Research Committee of the British Society Optimum duration of anticoagulation for deep vein thrombosis and pulmonary embolism. Lancet 1992; 340: 873.
73.     Shulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661.
74.     Sanson BJ, Lensing AW, Prins MH, et al. Safety of low-molecular weight heparinin pregnancy: a systematic review. Throm Haemost 1999; 81: 668.
75.     Hall JAB, Pauli RM, Wilson KM. Maternal and fetal sequelae or anticoagulation during pregnancy. Am J Med 1980; 68: 626.
76.     Prandoni P, Lensing AWA, Buller HR, et al. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128.
77.     Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight based heparin dosing nomogram compared with a “standard care” nomogram: A randomized controlled trial. Ann Intern Med 1993; 119: 874-81.
78.     Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154: 49-56.
79.     Simonnean G, Sors H, Charbonnier B, et al. A comparison of low molecular weight heparin with unfractioned heparin acute pulmonary embolism. N Engl J Med 1997; 337: 663-9.
80.     Leizoroviez A, Simonneaud G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: A meta analysis BMJ 1994; 309: 299-304.
81.     Siragusa S, Cosmi R, Piovella F, Hirsh J, Ginsberg JS. Low molecular weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta analysis. Am J Med 1996; 100: 269-77.
82.     Clagett GP, Anderson FA Jr, Geerts W, et al. Prevention of venous thromboembolism. Chest 1998; 114:531s.
83.     Enoxacan Study Group: Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venography assessment. Br J Surg 1997; 84:1099.
84.     Agnelli G, Piovella F, Buon Cristiani P, et al. Enoxaparin plus compression stockings compared with compression stocking alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998; 339: 80-5.

---

Regresar